Open public tenders that use the words in this company's products.
Tap a service to see where it is written.
Medi Era Life Science is a global Life Science company established on March 23, 2015, with a mission to provide affordable quality medicines. They focus on production and supply chain management for the Department of Health & Family Welfare, contributing to reducing infant and maternal mortality rates and managing non-communicable diseases. The company is also involved in the research and development of new equipment for hospitals, educational laboratories, and AI Labs, aiming to build frontier AI systems. They offer EPC solutions for industrial and infrastructure projects and have upgraded their warehouses to comply with WHO Guidelines for Good Storage Practice (GSP) and Good Distribution Practices (GDP).
These are entries in government registers. BharatSeal has not checked them separately.
Record completeness: 4 of 7 records on file
Not on record: GST registration, Udyam registration (MSME), Income-tax PAN
Export details the company has shared.
7 facts · 0 checked · 4 on record or declared · 3 unknown
Checks confirm records. They do not prove quality or delivery.
Life Science, Healthcare, Biopharma, Pharmaceutical
Faridabad, HR, India
No. Medi Era Life Science Private Limited has not claimed its BharatSeal profile. Registry records on this page are on record in government registers; BharatSeal has not checked them separately.
Medi Era Life Science Private Limited was incorporated in 2020 per Ministry of Corporate Affairs records under CIN U33100HR2020PTC089233. The company has been operating for 6 years, with the registration auditable on mca.gov.in.
Medi Era Life Science Private Limited's current directors include D P Mishra, Pradosh Mohanty, D. Gouri Sankar Achari. Director records are sourced from the MCA21 corporate registry and reflect the latest filing with the Ministry of Corporate Affairs.
Yes — exports to Abroad.
Send an enquiry through BharatSeal. Every enquiry is logged so you have a record of the conversation.